SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome. The study will compare three groups: dapagliflozin plus standard therapy, empagliflozin plus standard therapy, and standard therapy alone. The primary objective is to assess whether SGLT2 inhibitors reduce proteinuria, maintain remission, and prevent relapse. Secondary objectives include evaluating effects on kidney function (eGFR, serum creatinine) and monitoring safety outcomes. Participants will continue their baseline standard care and will be followed for 6 months with regular clinical evaluations, laboratory tests, and adverse event monitoring.

NCT Number	NCT07214818
Lead Sponsor	Mansoura University
Conditions	Nephrotic Syndrome
Enrollment	75 participants
Start Date	2025-11-15
Primary Completion	2026-07-05 (estimated)
Study Completion	2026-09-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-09